David Craig's The New Rules of Biotech: A Founder's Guide to Building Great Companies is now available in hardcover ($29.99) and as an audiobook on Google Play, joining the previously released paperback ($21.99) and Kindle ($11.99) editions on Amazon. The book addresses the shift in biotech company building since 2021, when capital has become more expensive, FDA standards have tightened, and the Inflation Reduction Act has altered drug economics before approval. Investors now prioritize capital efficiency and clear value creation over speculative funding.
Drawing from his experience founding and running a preclinical biotech, Craig provides guidance on selecting between platform and asset strategies, choosing affordable modalities, raising seed rounds based on milestones, and using non-dilutive capital strategically. The book covers IND-enabling work, CMC, clinical decisions, term sheets, board dynamics, business development, and exit options like acquisitions and IPOs. Each chapter includes takeaways for operators and separate insights for investors and advisors.
The book's origin stems from Craig's family connection to RYR-1 related congenital muscular dystrophy, reinforcing the argument that biotech company building carries responsibility beyond financial returns. "The hardcover is there for the people who want a durable copy on the desk, the paperback and Kindle for everyone else, and the audiobook on Google Play for those who prefer to listen on the move," said Craig. "The message is the same across all of them: build for the market that exists now, not the one that existed in 2021."
Published by D. Craig Consulting LLC, the book is available at Amazon (hardcover), Amazon (paperback), Amazon (Kindle), and Google Play (audiobook).
